Entecavir is a potent antiviral drug primarily used for the treatment of chronic hepatitis B virus (HBV) infection. It belongs to the class of nucleoside analog reverse transcriptase inhibitors, which work by inhibiting viral DNA polymerase, thereby preventing viral replication. Entecavir was first discovered in the late 1990s and approved for medical use in the early 2000s, marking a significant advancement in HBV therapy due to its high efficacy and low resistance profile compared to earlier treatments like lamivudine. Over time, it has become one of the preferred first-line therapies for managing chronic hepatitis B, improving long-term liver outcomes for patients worldwide.
Image
